Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Introduces Marq to Further Unify its Global Logistics Platform Within its Real Estate Business1.12.2025 13:00:00 EET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it is consolidating its global logistics real estate platforms under a single brand, Marq Logistics (“Marq”). The newly launched brand, Marq, will represent Ares’ vertically integrated global logistics real estate platform managing facilities that total more than 600 million square feet across the Americas, Europe and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201173799/en/ Marq brings together Ares’ vertically integrated logistics real estate platform in North America and Europe, including Ares Industrial Management, with the global GLP logistics real estate platform outside of China. This follows Ares’ acquisition of the international business and certain affiliates of GLP Capital Partners Limited, which closed in March 2025. With Marq, Ares combines its scale, expertise and integrated logis
Prodalim Continues Its Accelerated Strategic Transformation With the Acquisition of René Laurent, a Leading Beverage Flavours Company Based in Grasse area, France1.12.2025 12:42:00 EET | Press release
Prodalim, a global leader in Juice and specialty ingredients solutions, announced today the acquisition of René Laurent, a leading beverage flavours company, from International Flavours & Fragrances Inc. (IFF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126582710/en/ René Laurent site, Le Cannet, France Established in 1885 in Grasse area, the capital of the flavours and fragrances industry in southern France, René Laurent is a century-old, trusted brand specializing in beverage flavours solutions and unique aromatic Ingredients. The company partners with leading multinational customers and local champions in the beverage industry, offering deep expertise in complex, tailor-made flavour development, including syrups, liqueurs, naturals and coffee. Its extensive flavour library and distinctive in-house distillation and extraction capabilities make René Laurent a respected expert in complex and customized formulations. R
PUMA Opens its Biggest European Flagship Store in the Heart of London, Bringing the Best of the Brand Closer to Consumers1.12.2025 10:00:00 EET | Press release
PUMA has opened the doors to its largest-ever European flagship store on Oxford Street in London, which will bring the best of the company’s products and immersive storytelling closer to consumers in one of the busiest shopping destinations in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201979895/en/ PUMA has opened the doors to its largest-ever European flagship store on Oxford Street in London, which will bring the best of the company’s products and immersive storytelling closer to consumers in one of the busiest shopping destinations in Europe. The new flagship store, located just seconds from Selfridges and Bond Street Tube Station, spans 24,000 square-feet and features PUMA’s industry-leading innovations, such as running technology NITRO™, its football boots FUTURE, ULTRA and KING, as well as its current range of lifestyle products. “The opening of our Oxford Street flagship is an exciting moment for PUMA,
Wayve Acquires Quality Match to Strengthen Data Quality and Safety for AI Driving Systems1.12.2025 10:00:00 EET | Press release
Wayve, the leader in Embodied AI for autonomous driving, today announced the acquisition of Quality Match, a German startup known for its expertise in data quality assurance for computer vision datasets and artificial intelligence. This acquisition reflects Wayve's continued investment in data accuracy as a cornerstone of safe and scalable autonomous driving. Founded in 2019, Quality Match brings deep expertise in interpreting and analysing data used to train AI models for applications such as advanced assisted and automated driving. As Wayve advances toward the commercial deployment of its AI Driver software, integrating Quality Match strengthens its ability to efficiently develop high-quality, auditable datasets that are essential for building reliable and explainable AI models. Quality Match’s team of 20 specialists, based in Germany, will join Wayve's global operations. The acquisition expands Wayve's presence in the country following the launch of its Testing and Development Hub n
L&T Technology Services Transforms Respiratory Diagnostics with NVIDIA AI-Powered Digital Twin Technology1.12.2025 09:30:00 EET | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & R&D Consulting Services, today announced the development of a next-gen AI-powered digital twin platform for respiratory diagnostics and lung navigation. Combining LTTS’ expertise in platform engineering, AI-driven diagnostics, connected health systems and advanced imaging and visualization with cutting-edge NVIDIA AI infrastructure, LTTS aims to deliver scalable, low-latency solutions that enhance diagnostic precision and improve accessibility for healthcare providers worldwide. To be unveiled at the Radiological Society of North America (RSNA) 2025, the LTTS solution integrates with CT imaging and leverages deep learning models to create a 3D digital twin of lung anatomy, providing visualization of airways, blood vessels, lung lobes and lesions. Powered by NVIDIA MONAI for medical image segmentation and NVIDIA TensorRT for optimized AI inference, the biological digital twin enables interactive visualiza
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom